abbvie stock forecast 2030

Read our dividend analysis for ABBV. I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more. These are Immunology, Oncology, Neurology, Virology and Eye Care. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB (my tables and forecasting). Let's begin our analysis with the immunology division. Please. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. And never invest or trade money you cannot afford to lose. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. Please log in to your account or sign up in order to add this asset to your watchlist. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions) . View which stocks are hot on social media with MarketBeat's trending stocks report. On 14 January 2022, the FDA approved Abbvies arthritis treatment drug, Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active ulcerative colitis. In other words, no Humira, no problem! It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. Please disable your ad-blocker and refresh. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. Skyrizi has shown superiority to Humira in fields such as plaque psoriasis by a statistically significant amount, with a comparable safety profile, whilst Rinvoq has shown superiority in e.g. On average, they expect the company's stock price to reach $161.12 in the next twelve months. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. If you have an ad-blocker enabled you may be blocked from proceeding. Trading CFDs is high risk and is not suitable for everyone. As of February 15th, there was short interest totaling 11,710,000 shares, an increase of 13.7% from the January 31st total of 10,300,000 shares. In this article we take a closer look at the Abbvie stock forecast, after analysing the firms latest earnings, price moving news and analyst comments. Psoriatic arthritis is also adding significantly to Skyrizi's momentum, where we are now approved in 54 countries. If you rely on the information on this page then you do so entirely on your own risk. Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. Management believes these 2 drugs could one day generate $15bn in peak sales, going a long way to solving the Humira loss of exclusivity ("LOE") problem. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. Zscaler, Inc Plummets, Is It Time To Buy The Dip? . In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ). AbbVie's post-Humira LOE plans are not riskless, and its targets are ambitious, but nevertheless I see no harm in picking up shares in the Pharma at the current price, accepting a generous 4% dividend, and likely benefitting from share repurchases and a steadily growing share price until 2030. What is AbbVie's stock price forecast for 2023? I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. AbbVie has a P/B Ratio of 15.97. I write about Biotech, Pharma and Healthcare stocks and share investment tips. $163.64. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. on the strength of its future rather than present portfolio. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. That certainly won't derail the oncology division however. I had felt this could be an issue for Skyrizi and Rinvoq, given it is rare for a drug to be as dominant as Humira was, but although the level of competition is fierce, both drugs are more than meeting expectations, and with the entire auto-immune market worth as much as $45 - $50bn, it does seem possible that Skyrizi and Rinvoq could one day generate >$20bn revenues between them, as management hopes. American biopharmaceutical company Abbvie (ABBV) has surged nearly 13% year to date (YTD), and 35% year-over-year (YOY), as of 30 June. Finally, eye-care - another division inherited from Allergan - has been performing well for AbbVie although I am not expecting particularly strong growth from the current product portfolio. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. (my table and forecasts). What is Richard A. Gonzalez's approval rating as AbbVie's CEO? That figure suggests a forward Price to Earnings ("P/E") ratio of ~10x, which is well below the US Big Pharma sector average of ~23x, although it should be noted that the GAAP/non-adjusted EPS may be only significantly lower than the adjusted figure, based on adjusted EPS of $6.52 across H1'22, and GAAP EPS of $3.03 over the same period. See what's happening in the market right now with MarketBeat's real-time news feed. (AbbVie data). All times are ET. In the U.S. dermatology segment, where approximately 30% of patients exhibit both skin and joint involvement, Skyrizi is already achieving an in-play patient share of nearly 20%. As we can see, AbbVie is likely to generate some impressive cash flow based on its operating margins, which begin at 32%. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. Slide from JPM Conference 2022 presentation. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? Retail sales were up but so was inflation which meant more volatility for stocks. AbbVie is a leading dividend payer. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. Nevertheless, AbbVie is clearly under huge pressure to protect its dominance in the immunology markets, and the signs are it has been able to do just that thanks to the launches of 2 new drugs - Skyrizi and Rinvoq. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. All rights reserved. In February, a Phase 3 induction study saw positive top-line results. call (03) 8658 0539 support.au@capital.com. This could present more profit potential for drugmakers as well as investors. AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. Is this happening to you frequently? AbbVie could be the biggest global Pharma by revenue generation in 2028. The S&P 500 (US500) lost 9.1%, the Dow Jones (US30) slid 9.7%, and the Nasdaq Composite fell 23% during the same period. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. I have no business relationship with any company whose stock is mentioned in this article. According to AbbVie CEO Rick Gonzalez, speaking on the Q2'22 earnings call, "Skyrizi's total prescription share of the U.S. biological market (in psoriasis) has increased to approximately 26%", and". Although investing in AbbVie isn't riskless, it is advisable based on what we know about the company. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. Within the oncology division sales of Imbruvica fell 17% year-on-year. Please. As of 30 June, analysts price predictions compiled by MarketBeats and long-term forecasts by Wallet Investor projected that the ABBV stock price could rise. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. contact@marketbeat.com My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. I am not receiving compensation for it (other than from Seeking Alpha). The above table shows quarterly and annual product revenues going back to FY20, whilst the last 4 columns show revenue growth percentage between FY20 and FY21, then revenue growth between Q2'21 and Q2'22, the sequential (quarter on quarter) growth, followed by product sales as a percentage of revenues. After 2022 Humira's row is shaded yellow to signify patent expiry. Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions). Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. The total revenue in 2021 was $56.20 billion with a 31% operating margin. AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. 8.05% I wrote this article myself, and it expresses my own opinions. First we can take a quick look at what a forward income statement for AbbVie might look like to 2030. Projections are based on making fundamental and technical studies of the ABBV stock price performance. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. AbbVie discounted cash flow analysis. I have not managed to match management's ambitious high-single-digit growth figures from 2025 - 2023, despite anticipating 6% growth for nearly all products in that period. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). PEG Ratios above 1 indicate that a company could be overvalued. AbbVie Inc. is a US-based biopharma company with global operations. This suggests a possible upside of 3.2% from the stock's current price. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S. r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Build a CFD portfolio with your favourite companies. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. Finally, AbbVie was able to raise its financial . Read the conference call transcript. All rights reserved. The company employs 50,000 workers across the globe. Your current $100 investment may be up to $188.28 in 2028. Epcoritamab alone will not be sufficient to get AbbVie where it wants to be - despite some analysts believing it will be the highest grossing Pharma revenue wise by 2026. The material provided on this website is for information purposes only and should not be understood as an investment advice. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? Disclosure: I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. (6.33% Upside) Based on 15 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. Sign in to your free account to enjoy all that MarketBeat has to offer. My No. Compare Top Brokerages Here. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. writing - trading down slightly from its all-time high of >$160 achieved in early December last year. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. It is generally accepted however that 2023 will see the entrants into the US market of several generic versions of Humira - which works by inhibiting Tumor Necrosis Factor ("TNF"), an inflammation causing protein - from the likes of Viatris (VTRS), Organon (OGN), Pfizer (PFE), Amgen (AMGN), and several more companies involved in the development and sale of generic or biosimilar drugs. AbbVie declared a quarterly dividend on Thursday, February 16th. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. Receive regular, detailed analysis focused on biotech and healthcare stocks. AbbVie product revenue forecasts to 2030. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. As of 2023 February 22, Wednesday current price of ABBV stock is 151.340$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Abbvie stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. My detailed modeling suggests there is 15-20% upside to look forward to in the short term and that ABBV stock remains a solid long-term buy opportunity for investors. This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. The company issued revenue guidance of -. Move your mouse over a quarter or year to see how estimates have changed over time. Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience. It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. The stock projection varied from the low price target of $135 to the high of $200. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. I am not receiving compensation for it (other than from Seeking Alpha). The five-year dividend growth rate is just below 18%. The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. AbbVie's success - as its shareholders will doubtless be aware - stems from the runaway success of its immunology drug Humira, which is indicated for a range of autoimmune conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Hidradenitis Suppurativa and Ankylosing spondylitis. Investors needn't panic however - Humira's replacements are expected by AbbVie's CEO to generate even higher revenues per annum. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. Factset: FactSet Research Systems Inc.2019. View AbbVie's Short Interest. To summarize, Humira may be going off-patent, but is more than capable of delivering double-digit billion revenues for another 3-4 years, and even in 2030, it could be amongst the top 20 best-selling drugs worldwide. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. AbbVie's Dividend and Valuation. 326 E 8th St #105, Sioux Falls, SD 57103 You should do your own research and never invest money you cannot afford to lose. The company reported its first revenue for Botox competitor Daxxify. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.79%. What guidance has AbbVie issued on next quarter's earnings? To be sure, AbbVie is modeling for a tough year in 2023 for the aesthetics market. This indicates that AbbVie will be able to sustain or increase its dividend. Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. 1 dividend stock for a LIFETIME of income. Wallet Investor suggested that the price could hit $300.386 in June 2027. The major market events for the week ahead right in your inbox. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. 16 analysts have issued 12-month price targets for AbbVie's shares. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. 2022 Cable News Network. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. ABBV-916 is therefore a real opportunity for AbbVie to develop a more effective and safer drug in the same class and claim a sizeable share of a 6m patient market. In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. I have no business relationship with any company whose stock is mentioned in this article. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold, February 24, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com. I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. View our ABBV earnings forecast. Management are very optimistic on Vraylar, with Gonzalez describing it as "now the only antipsychotic that is a dopamine and serotonin partial agonist approved for the treatment of the most common forms of depression, Bipolar 1 and MDD" and targeting >$5bn peak sales. What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. As such, I have decreased my own expectations for 2022 based on simply doubling H1'22 revenues to get a FY22 figure, and downgrading growth expectations to 3% per annum until 2026. In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. Sales are expected to recover in H2'22, however, and forecast year-on-year growth. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.

Rotating Gravity Bong Diy, Danny Higginbotham Leaving Sky Sports, King's Own Scottish Borderers Association, Peninsula Chicago Room Service Menu, Articles A